Literature DB >> 19055643

Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.

Sara Vander Borght1, Mina Komuta, Louis Libbrecht, Aezam Katoonizadeh, Raymond Aerts, Steven Dymarkowski, Chris Verslype, Frederik Nevens, Tania Roskams.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to multidrug resistance (MDR). Recent studies showed that part of HCC could be of progenitor cell origin. Because some MDR-conferring transporters [multidrug resistance-associated protein 1 (MRP1), MDR1, MRP3 and breast cancer resistance protein (BCRP)] are expressed in hepatic progenitor cells (HPCs), expression in HCC might reflect a progenitor cell origin and provide the tumour cells with a MDR phenotype.
METHODS: The transcriptional profile of transporter genes was assessed in 139 HCCs earlier subjected to global gene expression analysis. In addition, we performed real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry for MRP1, MRP3, MDR1, BCRP and biliary/HPC markers keratin 7 and/or keratin 19 (K7/K19) on an independent set of 23 HCCs and surrounding liver.
RESULTS: Micro-array analysis showed that MRP1 was the only transporter with increased mRNA levels in HCC compared with the surrounding tissue. MRP1 mRNA levels were significantly higher in HCCs with poor survival and the 'hepatoblast subtype' of HCC, thought to be derived from HPCs. In 11 of 23 HCCs of the independent set, we found a diffuse protein expression of MRP1 compared with negative hepatocytic expression observed in normal (surrounding) hepatocytes. MRP1 was expressed in K19(+) non-neoplastic HPCs and K19(+) tumour cells. In addition, MRP3 and BCRP were expressed in K7/K19(+) tumour cells. MRP1 expression was high in poorly differentiated HCCs, large tumours (>7 cm) and microvascular invasive tumours.
CONCLUSIONS: MRP1 correlated with K19 mRNA and protein expression in two independent series of HCC. In addition, MRP1 was, together with MRP3 and BCRP, colocalized with K7/K19 in the tumour. Therefore, MRP1 expression could be a reflection of the HPC origin of this subgroup of HCCs and may result in an aggressive tumour phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055643     DOI: 10.1111/j.1478-3231.2008.01889.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  38 in total

1.  Establishment of a human hepatoma multidrug resistant cell line in vitro.

Authors:  Yuan Zhou; Xian-Long Ling; Shi-Wei Li; Xin-Qiang Li; Bin Yan
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy.

Authors:  Zheng Su; Gaojie Liu; Tingfeng Fang; Yang Wang; Huayao Zhang; Shanglin Yang; Jinxing Wei; Zejian Lv; Langping Tan; Jianping Liu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 3.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

Review 4.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 5.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

6.  Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.

Authors:  Caecilia Hc Sukowati; Natalia Rosso; Lory S Crocè; Claudio Tiribelli
Journal:  World J Hepatol       Date:  2010-03-27

7.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.

Authors:  Shaymaa M M Yahya; Shadia A Fathy; Zakaria A El-Khayat; Safinaz E El-Toukhy; Ahmed R Hamed; Marwa G A Hegazy; Heba K Nabih
Journal:  Indian J Clin Biochem       Date:  2017-04-21

9.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

10.  ABC transporters in cancer: more than just drug efflux pumps.

Authors:  Jamie I Fletcher; Michelle Haber; Michelle J Henderson; Murray D Norris
Journal:  Nat Rev Cancer       Date:  2010-01-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.